In addition, we thought it would be interesting to ask some of the clinicians who have been in the field of cutaneous lymphoma for many years to share their perspectives on the changes they have seen and their perspectives on the future. [...] Stanford just presented early data on personalized/precision management in MF/SS at the SID meeting, and we believe this is the future! There is still a lot of work to do still to validate and refine; the more we learn about the biologic and molecular mechanisms of CTCL, the better we can target and personalize/be precise with our treat- ments in the future. [...] Riding in the back of the ambulance with my mother to the hospital, I was texting with another patient in the trial who had a nearly identical reaction to her first infusion with mogamulizumab, and who subsequently responded very well to the treatment. [...] We were devastated! We New Board reached out to Susan Thornton, the CEO of the Cutaneous Lymphoma Foundation, and she provided incredible moral Member support and reached out to the sponsor of the trial on our behalf to see if there were any other ways Mom might still be able In June, the Cutaneous to receive the treatment (e.g. [...] We are given opportunities You have taken a step forward through this technology to try and personalize the treatment, or use preci- sion therapy that we know inhibits the specifically mutated proteins that by participating in the cuta- are critically involved in the origin of the disease.
- Pages
- 12
- Published in
- United States of America
